Stockscreener 앱 받기
3.17
1.28%
0.04
시간 외 거래:
3.17
전일 마감가:
$3.13
열려 있는:
$3.06
하루 거래량:
2.64M
Relative Volume:
0.95
시가총액:
$845.97M
수익:
-
순이익/손실:
$-244.17M
주가수익비율:
-3.247
EPS:
-0.9763
순현금흐름:
$-144.77M
1주 성능:
+2.59%
1개월 성능:
-23.43%
6개월 성능:
+2.59%
1년 성능:
+35.47%
1일 변동 폭
$3.03
$3.24
1주일 범위
$3.03
$3.4465
52주 변동 폭
$1.26
$6.55
사나 바이오테크놀로지 Stock (SANA) Company Profile
명칭
Sana Biotechnology Inc
전화
(206) 701-7914
주소
188 EAST BLAINE STREET, SUITE 350, SEATTLE
Compare SANA vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SANA
Sana Biotechnology Inc
|
3.17 | 835.29M | 0 | -244.17M | -144.77M | -0.9763 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
사나 바이오테크놀로지 Stock (SANA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-24 | 개시 | Wedbush | Outperform |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-03-18 | 업그레이드 | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-03-14 | 개시 | Jefferies | Buy |
| 2025-01-08 | 업그레이드 | TD Cowen | Hold → Buy |
| 2024-11-05 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-06-26 | 개시 | Rodman & Renshaw | Buy |
| 2024-01-16 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-09-25 | 개시 | JMP Securities | Mkt Outperform |
| 2023-09-05 | 개시 | Citigroup | Buy |
| 2023-08-14 | 개시 | TD Cowen | Market Perform |
| 2023-05-02 | 개시 | H.C. Wainwright | Neutral |
| 2021-03-01 | 개시 | BofA Securities | Buy |
| 2021-03-01 | 개시 | Goldman | Neutral |
| 2021-03-01 | 개시 | JP Morgan | Neutral |
| 2021-03-01 | 개시 | Morgan Stanley | Overweight |
모두보기
사나 바이오테크놀로지 주식(SANA)의 최신 뉴스
Sana Biotechnology (SANA) appoints industry veteran Brian Piper as new CFO - MSN
Bull Run: Will Sana Biotechnology Inc stock hit new highs in YEAR2026 Outlook & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Breakouts Watch: Can Sana Biotechnology Inc be the next market leaderDay Trade & High Accuracy Buy Signal Tips - baoquankhu1.vn
H.C. Wainwright reiterates Sana Biotechnology stock buy rating - Investing.com
Sana Biotechnology reports 14-month data on diabetes cell therapy By Investing.com - Investing.com India
Integral Health Asset Management LLC Has $7.10 Million Stock Position in Sana Biotechnology, Inc. $SANA - MarketBeat
Morgan Stanley Maintains Overweight on Sana Biotechnology, Inc. (SANA) March 2026 - Meyka
Morgan Stanley reiterates Sana Biotechnology stock rating on diabetes data By Investing.com - Investing.com Canada
Sana Biotechnology (NASDAQ:SANA) Trading Up 7.8%Here's What Happened - MarketBeat
Sana Biotechnology Announces Continued Positive Clinical Results Through 14 Months from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression - Bitget
Sana Biotechnology reports 14-month data on diabetes cell therapy - Investing.com
Analysts Offer Insights on Healthcare Companies: Sana Biotechnology (SANA) and Rapport Therapeutics, Inc. (RAPP) - The Globe and Mail
Earnings Report: Will Sana Biotechnology Inc benefit from sector rotation2026 Earnings Surprises & Consistent Return Investment Signals - baoquankhu1.vn
SANA: Hypoimmune and in vivo CAR T platforms advance toward clinical trials, with key data expected soon - TradingView
Sana (SANA) CEO Steve Harr vests RSUs and uses 24,345 shares for tax - Stock Titan
Sana Biotechnology (SANA) officer exercises RSUs and withholds shares for taxes - Stock Titan
VIX Spike: Can Sana Biotechnology Inc be the next market leader2026 Chart Watch & Comprehensive Market Scan Reports - baoquankhu1.vn
Sana Biotechnology (SANA) Expected to Announce Quarterly Earnings on Monday - MarketBeat
Sana Diabetes Data And Funding Moves Reframe Risk For NasdaqGS SANA Investors - Sahm
SANA Should I Buy - Intellectia AI
Aug Drivers: Is Sana Biotechnology Inc attractive at current valuation2025 Market Trends & Short-Term High Return Ideas - baoquankhu1.vn
Sana Biotechnology (SANA) CEO granted 200,000 RSUs and 900,000 stock options - Stock Titan
TD Cowen reiterates Buy rating on Sana Biotechnology stock By Investing.com - Investing.com Canada
TD Cowen reiterates Buy rating on Sana Biotechnology stock - Investing.com UK
Q1 EPS Estimate for Sana Biotechnology Lowered by Analyst - MarketBeat
AI Adoption Exposes Sana Biotechnology to Rising Data, Compliance, and Reputational Risks - The Globe and Mail
Sana Biotechnology (NASDAQ:SANA) Stock Price Down 9.7% After Analyst Downgrade - MarketBeat
What is HC Wainwright's Forecast for SANA FY2030 Earnings? - MarketBeat
Seattle InnoCajal raises $96M I Layoffs at Sana - The Business Journals
Sana Biotechnology (NASDAQ:SANA) Cut to Hold at Zacks Research - MarketBeat
Citizens reiterates Sana Biotechnology stock rating on pipeline progress By Investing.com - Investing.com Nigeria
Sana Biotechnology (SANA) officer exercises RSUs, uses 491 shares for taxes - Stock Titan
Sana Biotechnology Diabetes Data And CAR T Plans Shape Pipeline Outlook - simplywall.st
Sana Biotechnology (SANA) Q4 2025 Financial Results: Net Loss and Analyst OutlookNews and Statistics - IndexBox
Sana Biotechnology (NASDAQ:SANA) Price Target Lowered to $7.00 at HC Wainwright - MarketBeat
Sana Biotech's Q4 Net Loss Expands; Plans To Submit IND For SC451 In 2026; Stock Down - Nasdaq
Sana Biotechnology files for mixed shelf size not disclosedSEC filing - marketscreener.com
Sana Biotechnology Files For Mixed Shelf Size Not DisclosedSEC Filing - TradingView
Sana Biotechnology (NASDAQ: SANA) files ATM to raise up to $150M with TD Cowen - Stock Titan
Sana Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates - Bitget
Sana: Overview of Fourth Quarter Financial Results - Bitget
Sana Biotechnology Updates ATM Program to Support Development - TipRanks
Earnings Flash (SANA) Sana Biotechnology, Inc. Posts Q4 Adjusted Loss $0.16 per Share, vs. FactSet Est of $-0.14 - marketscreener.com
Going concern risk and focused pipeline at Sana Biotechnology (NASDAQ: SANA) - Stock Titan
Sana Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Sana Biotechnology (NASDAQ: SANA) sets $150.0 million ATM program - Stock Titan
SANA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Sana Biotechnology, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Sana Biotechnology, Inc. (SANA): A Bull Case Theory - Yahoo Finance
SANA SEC FilingsSana Biotechnology, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Sana Biotechnology (SANA) Stock Analysis: Exploring a Potential 104% Upside with Innovative Cell Therapies - DirectorsTalk Interviews
사나 바이오테크놀로지 (SANA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
사나 바이오테크놀로지 주식 (SANA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Harr Steve | President & CEO |
Mar 06 '26 |
Option Exercise |
0.00 |
41,666 |
0 |
7,918,596 |
| Wyrick Susan D. | See Remarks |
Mar 07 '26 |
Option Exercise |
0.00 |
3,250 |
0 |
200,583 |
| Wyrick Susan D. | See Remarks |
Mar 06 '26 |
Option Exercise |
0.00 |
10,416 |
0 |
197,333 |
| Wyrick Susan D. | See Remarks |
Mar 02 '26 |
Option Exercise |
0.00 |
1,525 |
0 |
187,408 |
| Wyrick Susan D. | See Remarks |
Jan 02 '26 |
Option Exercise |
0.00 |
7,500 |
0 |
188,290 |
| Wyrick Susan D. | See Remarks |
Dec 13 '25 |
Option Exercise |
0.00 |
3,400 |
0 |
181,663 |
| Wyrick Susan D. | See Remarks |
Dec 03 '25 |
Option Exercise |
0.00 |
10,000 |
0 |
180,828 |
| Wyrick Susan D. | See Remarks |
Jun 03 '25 |
Option Exercise |
0.00 |
10,000 |
0 |
170,395 |
1.20%
0.06%
자본화:
|
볼륨(24시간):